New hope for nigerian women with aggressive breast cancer
NCT ID NCT03879577
Summary
This study is testing how well a combination of two drugs (docetaxel and trastuzumab) works to shrink tumors before surgery in Nigerian women with a specific type of breast cancer called HER2-positive. The main goal is to see if the treatment can completely eliminate the cancer cells in the breast and lymph nodes by the time of surgery. Researchers will also track side effects, how long patients stay cancer-free, and their quality of life during and after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College Hospital, Ibadan, Nigeria
Ibadan, Nigeria
Conditions
Explore the condition pages connected to this study.